First-Line Nivolumab Plus Ipilimumab or Cabozantinib Followed by Second-Line Lenvatinib Plus Everolimus in Metastatic TFE-Rearranged Renal Cell Carcinoma
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07947277. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2 Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Cabozantinib as First-line Therapy, With Protocol-specified Lenvatinib Plus Everolimus in the Second-line, in Metastatic TFE-rearranged Renal Cell Carcinoma.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized phase 2 study evaluates the efficacy and safety of nivolumab plus ipilimumab versus nivolumab plus cabozantinib as first-line treatment in patients with metastatic TFE-rearranged renal cell carcinoma. Patients are randomly assigned to one of the two treatment groups. Following disease progression, patients receive protocol-specified second-line treatment with lenvatinib plus everolimus. The study assesses treatment outcomes during first-line therapy and across the planned treatment sequence.
Study identification
- NCT ID
- NCT07947277
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 12 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab (3mg/kg) Drug
- Ipilimumab (1mg/kg) Drug
- Cabozantinib 60 MG Drug
- Lenvatinib 18 MG Drug
- Everolimus 5 MG Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 5, 2024 (Actual)
- Primary completion
- Oct 12, 2026 (Actual)
- Completion
- Nov 12, 2026 (Actual)
- Last update posted
- Nov 18, 2026
2024 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| BUCARE | New York | New York | 10032 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07947277, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2026 · Synced Nov 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.